[Essential thrombocythemia: therapy with anagrelide].
Mazzucconi
M G
MG
Dip. di Biopatologia Umana, Università degli Studi La Sapienza, Roma.
Ferrari
A
A
Balduini
C L
CL
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors; D004341:Drug Evaluation; D005260:Female; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D008297:Male; D008533:Megakaryocytes / Q000187:drug effects; D010741:Phospholipases A / Q000037:antagonists & inhibitors; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D010976:Platelet Count / Q000187:drug effects; D011799:Quinazolines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013920:Thrombocythemia, Essential / Q000188:drug therapy*
D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; D010741:Phospholipases A; D015105:3',5'-Cyclic-AMP Phosphodiesterases; C021139:anagrelide
Trombocitemia essenziale: la terapia con anagrelide.